Harbin Pharmaceutical Group Co., Ltd. (SHA:600664)

SHA:600664 Revenue

Harbin Pharmaceutical Group had revenue of 4.12B CNY in the quarter ending June 30, 2026, with 4.31% growth. This brings the company's revenue in the last twelve months to 16.14B, down -0.14% year-over-year. In the year 2025, Harbin Pharmaceutical Group had annual revenue of 15.96B, down -1.31%. That makes Harbin Pharmaceutical Group the 4,411th largest company in the world by revenue and 558th in China.

• Revenue (ttm): 16.14B
• Revenue Growth: -0.14%
• P/S Ratio: 1.15
• Revenue / Employee: 1.61M
• Employees: 10,039
• Market Cap: 18.61B

Revenue Chart

Chart

Chart

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	15.96B	-211.79M	-1.31%
Dec 31, 2024	16.18B	719.28M	4.65%
Dec 31, 2023	15.46B	1.65B	11.93%
Dec 31, 2022	13.81B	1.01B	7.86%
Dec 31, 2021	12.80B	2.01B	18.66%

Data Source: S&P Global Market Intelligence Last updated: Aug 25, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Oct 6, 2026

Data Sources Report a data error